Riding the new wave of pharma market trends dk
-
Upload
danny-kosasih -
Category
Business
-
view
1.096 -
download
1
description
Transcript of Riding the new wave of pharma market trends dk
Riding the new wave of Pharma Market Trends
Content• Indonesia Pharma Market
• Therapeutic Area
• Top Corporations
• Top Products
• OTC Trends
• Business Deals
2009 2013 F-2017
3,005
4,710
7,493
OTC
ETHICAL
TOTAL MARKET
OKU YEN Sales ValueMAT
2013Q2 43%
57%
40%
58%
42%
60%
CAGR: +12%
CAGR: +12%
Indonesia Pharma MarketSales Value 2009-2013 & Forecast 2017
+11%
+13%
+17%
+9%
IMS ITMA MAT2013Q2
Pharma Market Size – South Asia RegionEUR 30.3 BIO, YoY +5.5%
-1.6%
+9.7%
+12%
+8.7%
+3.6%
+5.7%
+6.2%+20.6%
TAKEDA SA Region Report MAT2013Q2
Domestic Growth Comparison
Textile
Tobacco
Coal
Electronic
Clothing
F & B
Motor Vehicle
-5%
+2%
+7%
+2%
+20%
+20%
+6%
Pharma +12%
ID Economy
+6%
BPS Added Value 2010
• Key positive (+) forecast drivers: – Implementation of a National Health Insurance (NHI)
system – Expansion and improvement of the healthcare
infrastructure – Expansion of the private hospital sector
• Key negative (-) forecast drivers: – Encouragement of generic usage and growing pressure on
prices following implementation of the NHI system – Demographic factors as population growth slows
Pharma Market Forecast Drivers
IMS Prognosis MAT 2013Q2
Therapeutic Areas Growth
IMS Prognosis MAT 2013Q2
0% 5% 10% 15% 20% 25% 30%0%
5%
10%
15%
20%
25%
Series3; A ALIMENTARY T.& METABOLISM; 113072%
Series3; J SYSTEMIC ANTI-INFECTIVES; 70761%
Series3; N NERVOUS SYSTEM; 50667%
Series3; C CARDIOVAS-CULAR SYSTEM; 45436%
Series3; R RESPIRATORY SYSTEM; 44719%
Series3; M MUSCULO-SKELETAL SYSTEM; 26186%
Series3; D DERMATOLOG-ICALS; 25590%
Series3; V VARIOUS; 20195%
Series3; B BLOOD + B.FORMING ORGANS; 14612%
Series3; L ANTINEOPLAST+IMMUNOMODU
L; 11283%
CAG
R 5y
rs
Market Share
Pharma CAGR +12%
Therapeutic Areas Growth - Ethical
IMS Prognosis MAT 2013Q2
CAG
R 5y
rs
Market Share
0% 2% 4% 6% 8% 10% 12% 14% 16%0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
Series3; J SYSTEMIC ANTI-INFECTIVES; 70701%
Series3; A ALIMENTARY T.& METABOLISM; 42923%
Series3; C CARDIOVAS-CULAR SYSTEM; 38789%
Series3; N NERVOUS SYSTEM; 27231%
Series3; K HOSPITAL SO-LUTIONS; 18784%
Series3; R RESPIRATORY SYSTEM; 16354% Pharma
CAGR +12%
Therapeutic Areas Growth - OTC
IMS Prognosis MAT 2013Q2
CAG
R 5y
rs
Market Share
0% 2% 4% 6% 8% 10% 12% 14% 16%0%
5%
10%
15%
20%
25%
Series3; A ALIMENTARY T.& METABOLISM; 70150%
Series3; R RESPIRATORY SYSTEM; 28365%
Series3; N NERVOUS SYSTEM; 23436%
Series3; V VARIOUS; 18834%
Series3; D DERMATOLOG-ICALS; 16995%
Series3; M MUSCULO-SKELETAL SYSTEM; 11690%
Pharma CAGR +12%
IMS QPMU 2013Q2
Top 25 TC Level 3
Top Corporations
IMS ITMA MAT 2013Q2
Sales Trade Value Market Share CAGR 5yrs
Rank Top 20 Corporations Status 2009 2013 2009 2013 2013
IND TOTAL MARKET 3,005 4,710 100% 100% 12%
1 KALBE GROUP LOCAL 439 647 13% 12% 10%2 SANBE LOCAL 208 326 6% 6% 12%3 SOHO GROUP LOCAL 167 278 5% 5% 14%4 DEXA MEDICA GROUP LOCAL 175 272 5% 5% 12%5 PHAROS GROUP LOCAL 93 207 3% 4% 22%6 TEMPO GROUP LOCAL 146 200 4% 4% 8%7 NOVARTIS GROUP MNC 75 145 2% 3% 18%8 GLAXOSMITHKL GROUP MNC 86 135 3% 3% 12%9 FAHRENHEIT LOCAL 71 130 2% 2% 16%
10 SANOFI-AVENTIS GRP MNC 78 126 2% 2% 13%11 DARYA-VARIA GROUP LOCAL 81 118 2% 2% 10%12 KONIMEX LOCAL 60 116 2% 2% 18%13 BAYER INDONESIA MNC 94 113 3% 2% 5%14 MENSA GROUP LOCAL 89 112 3% 2% 6%15 KIMIA FARMA GROUP LOCAL 70 105 2% 2% 11%16 NOVELL PHARM LOCAL 53 103 2% 2% 18%17 PFIZER GROUP MNC 88 101 3% 2% 4%18 LAPI LOCAL 32 100 1% 2% 33%19 INTERBAT LOCAL 70 94 2% 2% 8%20 INDOFARMA LOCAL 56 87 2% 2% 12%21 B.INGELHEIM GROUP MNC 44 81 1% 2% 16%22 MERCK INDONESIA GP MNC 55 76 2% 1% 9%23 J&J MNC 44 68 1% 1% 12%
66% +12
Sales Trade Market Share Growth CAGR 5yrs
Rank Status 2013 2013 2013 2013
Top 20 Corporations in OTC 3,177 100% 11% 13%
1 KALBE GROUP LOCAL 445 14% 17% 15%
2 SANBE LOCAL 281 9% 16% 15%
3 DEXA MEDICA GROUP LOCAL 202 6% 16% 12%
4 NOVARTIS GROUP MNC 134 4% 10% 20%
5 SANOFI-AVENTIS GRP MNC 126 4% 8% 13%
6 FAHRENHEIT LOCAL 119 4% 17% 17%
7 PFIZER GROUP MNC 101 3% -1% 4%
8 KIMIA FARMA GROUP LOCAL 81 3% -4% 11%
9 MENSA GROUP LOCAL 80 3% 11% 13%
10 INDOFARMA LOCAL 77 2% 16% 11%
11 GLAXOSMITHKL GRP MNC 74 2% 16% 10%
12 BAYER INDONESIA MNC 67 2% 5% 9%
13 SOHO GROUP LOCAL 58 2% -3% 14%
14 OTSUKA GROUP LOCAL 57 2% 16% 9%
15 ACTAVIS MNC 56 2% 23% 28%
16 INTERBAT LOCAL 56 2% 9% 7%
17 DARYA-VARIA GROUP LOCAL 55 2% 7% 11%
18 B.INGELHEIM GROUP MNC 53 2% 20% 20%
19 PHAROS GROUP LOCAL 53 2% 5% 14%
20 ASTRAZENECA MNC 47 1% 12% 9%
Top Corporations - Ethical
IMS ITMA MAT 2013Q2
Sales Trade Market Share Growth CAGR 5yrs
Rank Status 2013 2013 2013 2013
Top 20 Corporations in OTC 2,134 100% 15% 11%
1 SOHO GROUP LOCAL 219 10% 25% 13%
2 KALBE GROUP LOCAL 202 9% -2% 2%
3 TEMPO GROUP LOCAL 179 8% 6% 8%
4 PHAROS GROUP LOCAL 154 7% 34% 26%
5 KONIMEX LOCAL 116 5% 11% 18%
6 DEXA MEDICA GROUP LOCAL 70 3% 10% 11%
7 DARYA-VARIA GROUP LOCAL 63 3% 17% 8%
8 GLAXOSMITHKL GRP MNC 61 3% 8% 14%
9 LAPI LOCAL 60 3% 79% 55%
10 NOVELL PHARM LOCAL 58 3% 30% 17%
11 BAYER INDONESIA MNC 46 2% 19% 0%
12 SANBE LOCAL 45 2% 7% -2%
13 INTERBAT LOCAL 38 2% 6% 8%
14 J&J MNC 35 2% -1% 9%
15 MERCK INDONESIA GP MNC 34 2% 7% 6%
16 MENSA GROUP LOCAL 32 1% -11% -6%
17 COMBIPHAR GROUP LOCAL 31 1% -3% 7%
18 B.INGELHEIM GROUP MNC 27 1% 12% 10%
19 MAHAKAM BETA FARMA LOCAL 27 1% 68% 45%
20 HISAMITSU PHARMA MNC 26 1% 38% 26%
21 KIMIA FARMA GROUP LOCAL 24 1% 9% 9%
22 TAISHO GROUP LOCAL 24 1% 4% 12%
Top Corporations - OTC
IMS ITMA MAT 2013Q2
Top ProductsSales Value
2013Market Share
CAGR 5Yrs
TOP 20 OTC PRODUCTS
PROMAG KLB 51.5 2% 11% NOURISH SKIN P-I 49.2 2% 14% IMBOOST SHO 40.1 2% 19% PARAMEX KOX 38.4 2% 18% BODREX TFC 33.9 2% 9% OMEPROS P-I 22.5 1% 110% NEO-RHEUMACYL TFC 21.2 1% 6% SALONPAS MEDICATED HSM 20.8 1% 24% HEMAVITON JRENG TFC 19.9 1% -4% BETADINE MKB 19.7 1% 47% CALCIUM-D-REDOXON B/S 19.4 1% 0% THROMBOPHOB NMK 19.0 1% 10% MIXAGRIP DKS 18.7 1% 8% ASTHIN SHO 18.5 1% 14% SUPER ESTER C TCN 17.9 1% 7% PRORIS P-I 16.5 1% 35% VIOSTIN DS P-I 16.2 1% 73% NEUROBION MCK 16.2 1% 8% COUNTERPAIN TIP 15.3 1% 13% MICROLAX P-I 14.5 1% 27%
Sales Value2013
Market Share
CAGR 5Yrs
TOP 20 ETHICAL PRODUCTS
DIOVAN NVR 29.1 1% 48% SUPER TETRA D.V 21.4 1% 9% LIPITOR PFZ 20.2 1% 9% PLAVIX S.A 18.5 1% 13% SOMADRIL COMP ATV 18.0 1% 41% TERFACEF SN5 16.3 1% 14% AMOXSAN SN5 15.5 0% 8% MICARDIS B.I 15.0 0% 62% NORVASK PFZ 14.6 0% -3% CEFAT SN5 14.4 0% 7% PANTOZOL NYE 14.1 0% 14% VENTOLIN GSK 14.0 0% 19% PLASBUMIN DPI 14.0 0% 26% CEFSPAN KLB 13.3 0% 11% CATAFLAM NVR 12.9 0% 29% RINGER LAKTAT(OGB) WIB 12.9 0% 14% NOVORAPID N-N 12.8 0% 90% PONSTAN PFZ 12.8 0% 0% NOVOMIX 30 N-N 12.2 0% 56% SPORETIK SN5 11.9 0% 20%
IMS ITMA MAT 2013Q2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Top 20 Products Over 3 MATs
IMS QPMU 2013Q2
OTC Trends
2009 MAT 2013Q20.0
200.0
400.0
600.0
800.0
1,000.0
1,200.0
1,400.0
1,600.0
1,800.0
2,000.0
114.2 45.2
1,260.2 1,892.0
OTCNutrition
Lifestyle19% Skin
Vita-min5%
Digestive / GI4%Laxative
3%Memory
1%Herbal11%
MAT 2013Q2 $ Share (%)
Sales in OKU YEN Share (%) CAGR2009 MAT 2013 Q2 2009 MAT 2013 Q209-'13
OTC + Nutrition 1,340.2 1,885.0 100.0% 100.0% 8.9%Lifestyle 339.4 363.9 24.7% 18.8% 1.8%Herbal 109.6 215.8 8.0% 11.1% 18.5%Digestive / GI 47.6 70.4 3.5% 3.6% 10.3%Skin Vitamin 42.9 101.5 3.1% 5.2% 24.0%Respi 34.2 52.3 2.5% 2.7% 11.2%Laxative 33.2 51.7 2.4% 2.7% 11.7%Memory 6.0 17.5 0.4% 0.9% 30.9%Others 761.5 1,064.1 55.4% 54.9% 8.7%
Business Partnership FormatsFormat Postive (+) Negative (-) Case Study
In-sourcing / Contract Sales ForceCo-partner is carrying and marketing Host-Partner products by commision based
• Full authority of marketing and promotion of the products
• No subject to production and COGS
• No subject to distribution margin (depends on MoU)
• Most of outsourced products are unpromoted which in mature/ declining growth
• To be ready for additional reporting system
• Subject to product management fee
• Ethica to MSD, for unpromoted products
• Dexa to Novartis, for unpromoted products
• InMark to Takeda, for established (legacy) products
• Abbot to GSK, for established & unpromoted products
Co-Marketing & Co-Promotionboth Host-partner and Co-partner are promoting the products but divided into agreed market segments (geographical, specialty, outlets type, etc)
• Partnership and gain support from one to another
• Clear market segmentation
• Clear marketing promotion & message
• Promotion startegy is controlled by partner company (CoC, reporting, markets)
• Dependent to the market segmentation
• Dependent to distribution coverage
• In-mark/Dexa and Pfizer, for Norvask
• In-mark/Dexa and Novartis, for Diovan
Bulk Purchasing Co-partner purchases the products at discounted price and then selling it using their own sales model
• Full control and authority for products management & marketing
• No market segmentation
• Huge risk of low sales required strong marketing investment
• Distribution hassle
• Pharos to Nycomed, for Albothyl
2nd BrandCo-Partner manufactures a generic of host-partner’s product
• Full control and authority for products management & marketing
• Market is already shaped• Follower advantage to
original brand
• Complex segmentation• Cannibalism • Confrontation in field force
level
• Dexa with Pfizer, for Norvask and Tensivask
• PT. Soho Farmasi (51%) joint venture with Frenesius Kabi (49%) to establish a new business entity, including Generics Factory
• PT Kalbe Farma Tbk (KLBF) and PT Indofarma Tbk (INAF) plans to conduct acquisitions this year
• PT Indofarma Tbk (INAF), strengthens its strategic alliance with PT Sysmex Indonesia, a Japan-based clinical laboratory
• PT Indofarma Tbk will invest 263 billion dollars for the development of their drug manufacturing capacity, ahead of the implementation of the national social security system of the early 2014.
• PT B Braun Indonesia develops IV fluid factory in Indonesia
Pharma Business Deals News Update
CO-OPETITION
2009 2013 F-2017
3,005
4,710
7,493
OTC
ETHICAL
TOTAL MARKET
OKU YEN Sales ValueMAT
2013Q2 43%
57%
40%
58%
42%
60%
CAGR: +12%
CAGR: +12%
Indonesia Pharma MarketSales Value 2009-2013 & Forecast 2017
+11%
+13%
+17%
+9%
IMS ITMA MAT2013Q2
THANK YOU